Hybio Pharmaceutical Co., Ltd.
300199
Clasificación en acciones
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Precio por acción
$3.69
Capitalización bursátil
$3.11B
Cambio (1 día)
-7.75%
Cambio (1 año)
21.56%
País
CN
Comercio Hybio Pharmaceutical Co., Ltd. (300199)
Categoría
Healthcare
Historial de dividendos de Hybio Pharmaceutical Co., Ltd. (300199)
Hybio Pharmaceutical Co., Ltd. (símbolo bursátil: 300199) realizó un total de 6 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: $0.49
Rentabilidad por dividendo (TTM): 0
La suma de todos los dividendos (ajustados por splits de acciones) es: $0.49
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Hybio Pharmaceutical Co., Ltd. (300199) desde 2012 hasta 2026
Pagos anuales de dividendos
| Año | Dividendo (ajustado por splits de acciones) | Cambiar |
|---|---|---|
| 2026 (TTM) | $0.2 | 0.00% |
| 2018 | $0.2 | 100.00% |
| 2017 | $0.1 | 300.00% |
| 2016 | $0.025 | -50.00% |
| 2015 | $0.05 | 0.00% |
| 2013 | $0.05 | -20.00% |
| 2012 | $0.0625 | 0.00% |
Lista de todos los pagos de dividendos
| Año | Dividendo | Cambiar |
|---|---|---|
| 2026 (TTM) | $0.2 | 0.00% |
| 2018 | $0.2 | 100.00% |
| 2017 | $0.1 | 300.00% |
| 2016 | $0.025 | -75.00% |
| 2015 | $0.1 | -50.00% |
| 2013 | $0.2 | -60.00% |
| 2012 | $0.5 | 0.00% |
Pagos de dividendos de empresas similares o competidoras
| Empresa | Número de pagos de dividendos | País |
|---|---|---|
| 13.00% |
DE
|
|
| 26.00% |
DE
|
|
| 55.00% |
JP
|
|
| 2.00% |
CH
|
|
| 39.00% |
IN
|
